AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo moved a step closer to a major label expansion for their blockbuster cancer therapy, Enhertu, after the U.S. FDA fast-tracked an application to treat patients with early-stage breast cancer at high risk of recurrence.
Agilent Technologies (NYSE:A) moved to significantly expand its clinical oncology presence on Monday, announcing an all-cash deal for Biocare Medical that adds a high-growth portfolio of cancer-staining antibodies and reagents.
Adial Pharmaceuticals (NASDAQ:ADIL) reported a significant reduction in annual net losses for 2025, as the clinical-stage biotech firm secures FDA alignment and strategic partnerships to transition its lead alcohol-use disorder candidate into Phase 3 trials.
PMV Pharmaceuticals (NASDAQ:PMVP) reported significant clinical momentum for its lead candidate, rezatapopt, bolstered by a fresh FDA Orphan Drug Designation and clinical results showing high response rates in late-stage ovarian cancer patients.
Immuneering (NASDAQ:IMRX) has achieved a 64% overall survival rate at 12 months in an ongoing Phase 2a clinical trial for its lead drug candidate, atebimetinib, in combination with chemotherapy for patients with metastatic pancreatic cancer.
Jade Biosciences (NASDAQ:JBIO) reported fourth-quarter and full-year 2025 financial results on Friday, highlighting a robust cash position and a clear clinical roadmap for its portfolio of monoclonal antibodies.
AtaiBeckley (NASDAQ:ATAI) reported fourth-quarter and full-year 2025 results on Friday, marking its first annual report since the transformative merger of atai Life Sciences and Beckley Psytech.
Pfizer (NYSE:PFE) significantly expanded its metabolic footprint on Friday, announcing that Chinese regulators have approved its GLP-1 receptor agonist, Xianweiying (ecnoglutide), for long-term weight management in overweight and obese adults.
Nutex Health (NASDAQ:NUTX) reported fourth-quarter and full-year 2025 results on Thursday, headlined by a massive leap in annual revenue and a new $25 million share repurchase program.
CorMedix (NASDAQ:CRMD) reported a significant return to profitability for the fourth quarter on Thursday, as the commercial rollout of its lead product, DefenCath, gained momentum alongside contributions from its newly acquired Melinta Therapeutics portfolio.
Tango Therapeutics (NASDAQ:TNGX) reported fourth-quarter financial results on Thursday that surpassed Wall Street’s bottom-line expectations, supported by a significant extension of its capital reserves.
Immatics (NASDAQ:IMTX), a Tübingen, Germany-based clinical-stage biopharmaceutical company developing T cell receptor (TCR)-based immunotherapies for the treatment of solid tumors, on Thursday reported a net loss of $41.6 million for its fourth quarter ended December 31, 2025.
